{"id":"rasagiline-mesylate-with-requip","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rasagiline irreversibly inhibits MAO-B, the enzyme responsible for dopamine breakdown in the brain, thereby increasing dopamine availability. Ropinirole directly stimulates dopamine D2 and D3 receptors on striatal neurons. Together, these complementary mechanisms enhance dopaminergic neurotransmission to alleviate motor symptoms of Parkinson's disease.","oneSentence":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:36:59.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (motor symptom management)"}]},"trialDetails":[{"nctId":"NCT00399477","phase":"PHASE4","title":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rasagiline mesylate with Requip","genericName":"Rasagiline mesylate with Requip","companyName":"Teva Neuroscience, Inc.","companyId":"teva-neuroscience-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management. Used for Parkinson's disease (motor symptom management).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}